financetom
Business
financetom
/
Business
/
Waymo to offer autonomous rides in Nashville on Lyft ride-hailing network
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Waymo to offer autonomous rides in Nashville on Lyft ride-hailing network
Sep 17, 2025 8:17 AM

(Reuters) -Alphabet's Waymo plans to start offering autonomous cab rides in Nashville next year in collaboration with ride-hailing firm Lyft ( LYFT ), the two companies said.

Riders in the Music City will initially be able to hail self-driving cabs through the Waymo app. As the service grows, riders will also be able to use the Lyft ( LYFT ) app to match with a Waymo vehicle, the companies said in a statement.

As part of the agreement, Lyft ( LYFT ) will invest an undisclosed sum in an autonomous vehicle fleet-management facility, where it will charge and maintain Waymo vehicles. Lyft's ( LYFT ) services should maximize the time Waymo's vehicles are in operation and reduce costs, the two companies said.

It would be the first commercial deployment of Waymo's driverless taxis on the Lyft ( LYFT ) ride-hailing network. Waymo already offers rides in Austin, Texas, and Atlanta through the Uber ( UBER ) app. 

Waymo's fleet in Nashville is expected to grow to hundreds of vehicles over time, according to the company. 

Waymo has been ramping up operations in the U.S. as the robotaxi race heats up. Tesla deployed a limited robotaxi service in Austin in June. The electric-vehicle company has said it plans to expand the service to the San Francisco Bay Area.

After starting in Phoenix in 2020, Waymo now offers paid driverless rides to the general public in the San Francisco Bay Area, along with parts of Los Angeles, Phoenix, Austin and Atlanta. 

In addition to Nashville, the company has plans to expand operations to Miami, Washington, D.C., Dallas and Denver. It also recently received a permit to begin testing its autonomous vehicles in New York City with a trained specialist behind the wheel.

(Reporting By Norihiko Shirouzu in Austin; Editing by Mike Colias and Muralikumar Anantharaman)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lazard Posts Increase in Assets Under Management for January
Lazard Posts Increase in Assets Under Management for January
Feb 12, 2025
08:19 AM EST, 02/12/2025 (MT Newswires) -- Lazard ( LAZ ) reported preliminary assets under management Wednesday of $233.02 billion as of Jan. 31, up from $226.33 billion a month earlier. The asset management firm reported a market appreciation of $6.1 billion, foreign exchange appreciation of $400 million, and net inflows of $300 million for January. ...
Kroger names PepsiCo executive David Kennerley as CFO
Kroger names PepsiCo executive David Kennerley as CFO
Feb 12, 2025
Feb 12 (Reuters) - Kroger ( KR ) said on Wednesday PepsiCo executive David Kennerley would succeed Todd Foley as the company's chief financial officer, effective April 3. Foley had taken over the role on an interim basis when former CFO Gary Millerchip stepped down last February. Kroger ( KR ) in December ended a two-year effort to merge with...
AnaptysBio's Rheumatorid Arthritis Drug Meets Primary Endpoint in Phase 2 Trial; Shares Rise
AnaptysBio's Rheumatorid Arthritis Drug Meets Primary Endpoint in Phase 2 Trial; Shares Rise
Feb 12, 2025
08:20 AM EST, 02/12/2025 (MT Newswires) -- AnaptysBio ( ANAB ) said Wednesday that a phase 2b trial of its investigational drug rosnilimab to treat moderate-to-severe rheumatoid arthritis achieved its primary and secondary endpoints. Patients in the study received either 100 milligram or 400 milligram doses of rosnilimab every four weeks, 600 milligrams every two weeks, or placebo, the company...
AbbVie, Xilio Collaborate on Tumor-Activated Immunotherapies
AbbVie, Xilio Collaborate on Tumor-Activated Immunotherapies
Feb 12, 2025
08:18 AM EST, 02/12/2025 (MT Newswires) -- AbbVie ( ABBV ) and Xilio Therapeutics (XLO) said Wednesday they are collaborating and have signed an option-to-license agreement to develop tumor-activated, antibody-based immunotherapies, including masked T-cell engagers. The companies said they will combine Xilio's tumor-activation technology with AbbVie's ( ABBV ) research and development efforts in oncology. As part of the deal,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved